Pfizer eyes FDA submission for new hemophilia drug

The latest stories trending on MedCity News.

Editor's Pick

Top Story On Heels of ASH Data, Pfizer Eyes FDA Submission for New Hemophilia Drug Pfizer already reported its experimental drug for hemophilia A and B met a pivotal study's goals of reducing bleeding episodes. During the annual meeting of the American Society of Hematology, the company presented a full look at the results, which are expected to support regulatory submissions soon. Sponsored Content Revolutionizing Virtual Primary Care Presented by MDLive and MedCity News MDLive President, Jon Salon details the latest enhancement to their virtual primary care offerings with chronic conditions and how the company's health coaching program will help patients stay engaged. Watch the full interview Networking At Its Finest & Best Rate Hurry, you have 1 week left to get the best rate on the best networking the industry has to offer. 2 days at the Ritz in Chicago, May 21-22, 2024. Connect with the best investors, VCs, most promising startups and so much more. Register Now to Save $700

Featured News

5 Trends Shaping Healthcare Business Strategies for 2024 Deloitte released a report predicting the key trends that will shape the healthcare landscape in 2024. Some of them include hospital M&A, health systems outsourcing departments and the increasing adoption of generative AI tools. The Need for an Upstream Approach to Address the Youth Mental Health Crisis Shifting the healthcare system to an upstream approach will take a lot of work, but young people desperately need it, and the healthcare system direly needs it as well. Solving One of the Most Overlooked Complications after Surgery: Medical Adhesive Related Skin Injuries Selection of the correct wound dressings and closure devices for patients remains an important factor in preventing MARSIs (Medical Adhesive Related Skin Injuries). Some of Your Doctors' Best Qualities are the Same Ones Stifling Your Healthcare Experience Although problems in US healthcare abound, the most insidious challenges are often tightly coupled with the industry's most appealing and instilled virtues — a highly selective and independent workforce, (b) an extremely low tolerance for risk, and (c) a high degree of professional oversight.

Resources

How To Enable Hyperpersonal Care Amid transitioning consumer expectations, an evolving care delivery model, and a significant workforce crisis, health systems need to change the way they do business and harness the right technology to create an effective solution. This webinar will feature expert panelists from Praia Health and Providence, interviewed by AVIA to discuss the benefits of adopting a hyperpersonal care model for patients and barriers that hold health systems back. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe